<DOC>
	<DOCNO>NCT01916265</DOCNO>
	<brief_summary>The ultimate goal PCDIAB project develop bi-hormonal pump ( insulin glucagon ) substitute pancreas facilitate tight euglycemic control patient T1DM .</brief_summary>
	<brief_title>Trial Compare Relative Pharmacodynamic Properties Different Glucagon Dosages</brief_title>
	<detailed_description>The study plan open , randomised 3-period cross-over patient T1DM . The study include total 6 complete patient . The study blind due exploratory nature . At 3 period , different blood glucose level establish 4 step ( 8 , 6 , 4 , 2.8 mmol/L ) , prefixed glucagon dose give per glucose level . The sequence glucagon dose strength three dosing day randomize .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Male female subject diabetes mellitus type 1 , define American Diabetes Association1 . Age ≥ 18 ≤ 65 year . Known suspected hypersensitivity trial product ( ) relate product . Receipt investigational medicinal product within 3 month 5 halflives IMP randomisation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>